Objectives To investi gate the association of soluble Fas ligand( sFasL) and soluble Fas receptor( sFas) with human chronic con gestive heart failure( CHF) . Methods The serum level of sFasL and sFas in 33 patients wi...Objectives To investi gate the association of soluble Fas ligand( sFasL) and soluble Fas receptor( sFas) with human chronic con gestive heart failure( CHF) . Methods The serum level of sFasL and sFas in 33 patients with CHF (13 in cardiac function class Ⅱ, 17 in class Ⅲ, 3 in class Ⅳ, NYHA) was assessed with enzyme - linked immunosorbent assay, and was compared with that of 18 age - , blood pressure - matched patients with car diac function class Ⅰ (NYHA). Results There was no difference in the level of sFasL between the two groups [CHF group: 231. 50 + / - 84. 50 (cardiac function class Ⅱ216. 50 + / - 96. 00 , class Ⅲ 226. 80 + / - 85. 70, class Ⅳ 244. 00 + / - 73. 00) vs. cardiac function class I group: 217. 50 + /-89. 00 pg/mL, P>0. 05]. However, the level of sFas was significantly higher in the patients with CHF than those of cardiac function class I group [CHF group: 1353. 30 +/-507. 71 (cardiac function class Ⅱ 1154. 85 + /-371. 20 , class Ⅲ1412.88 + /-493. 62, classⅣ1875. 67 + / - 806. 10) vs. cardiac function class I group: 983. 11+/ -461. 26 pg/mL, P<0. 05 ] . Conclusions sFasL was not associated with human CHF. However, the elevation of serum level of sFas was proportion to the severity of human CHF. sFas may play an important role in the patho- genesis of human CHF.展开更多
目的:探讨血清可溶性Fas(solub le Fas,sFas)和可溶性Fas配体(solub le Fas L igand,sFasL)在再生障碍性贫血(ap lasticanem ia,AA)患者血清中的变化及临床意义。方法:采用酶联免疫吸附双抗体夹心法检测30例再生障碍性贫血患者血清sFas...目的:探讨血清可溶性Fas(solub le Fas,sFas)和可溶性Fas配体(solub le Fas L igand,sFasL)在再生障碍性贫血(ap lasticanem ia,AA)患者血清中的变化及临床意义。方法:采用酶联免疫吸附双抗体夹心法检测30例再生障碍性贫血患者血清sFas、sFasL水平。结果:再生障碍性贫血患者血清sFas水平显著低于正常对照(P<0.01);重型再生障碍性贫血患者血清sFas水平明显低于慢性再生障碍性贫血(P<0.05);血清sFas浓度与再生障碍性贫血患者临床分型和疗效相关。血清sFasL水平在再生障碍性贫血患者和正常对照血清中含量差异无显著性(P>0.05)。结论:AA患者血清sFas水平降低,可作为反映AA病情严重程度和疗效观察的有效指标之一。展开更多
目的探讨多器官功能障碍综合征(multiple organ dysfunction syndrome,MODS)患者血清sFas和sFasL浓度在MODS诊断以及病情严重程度和预后判断中的临床意义以及与血清肿瘤坏死因子α(TNFα)水平的相关性。方法采用酶联免疫吸附法(ELISA)测...目的探讨多器官功能障碍综合征(multiple organ dysfunction syndrome,MODS)患者血清sFas和sFasL浓度在MODS诊断以及病情严重程度和预后判断中的临床意义以及与血清肿瘤坏死因子α(TNFα)水平的相关性。方法采用酶联免疫吸附法(ELISA)测定36例MODS患者血清sFas、sFasL和TNFα浓度,以急性生理学与慢性健康状况评分系统(APACHE)评分和改良MODS评分评估病情严重程度,比较MODS组与对照组〔包括非全身炎症反应综合征(SIRS)对照组和健康对照组〕以及MODS组内死亡和存活患者之间血清sFas、sFasL浓度的差异,分析患者血清sFas、sFasL和TNFα浓度与病情严重程度及血清sFas和sFasL与TNFα浓度的相关性。结果MODS患者血清sFas、sFasL浓度均明显高于非SIRS对照组和健康对照组(P<0.05或P<0.01),且与病情严重度评分均呈正相关(P均<0.01)。MODS患者中死亡组较存活组血清sFas、sFasL浓度明显升高(P均<0.05)。MODS患者血清TNFα浓度较非SIRS对照组和健康对照组明显增高,并与MODS组血清sFas、sFasL浓度呈高度正相关(P均<0.01)。MODS患者血清sFas、sFasL浓度随器官衰竭个数增加而升高。结论血清sFas、sFasL可用于临床MODS辅助诊断和协助判断病情严重程度及预后。TNFα可能促进了MODS中Fas/FasL系统表达上调。展开更多
文摘目的探讨基于主成分分析(principal component analysis,PCA)结合Logistic回归模型分析脑脊液可溶性Fas(soluble Fas,sFas)、Fas配体(soluble Fas ligand,sFasL)水平及压力参数对创伤性颅脑损伤患者术后继发脑积水的预测价值。方法选取2018-12/2021-12月由作者医院神经外科收治的260例创伤性颅脑损伤患者作为研究对象,对其临床资料进行回顾性分析,根据术后是否发生脑积水将患者分为继发脑积水组(n=48)和无继发脑积水组(n=212)。对患者的性别、年龄、手术前后格拉斯哥昏迷量表(Glasgow coma scale,GCS)、颅脑损伤部位、手术时间、手术前后脑室系统出血、术后颅内感染、术后大面积脑梗死、手术前后中脑导水管和环池结构、术后脑脊液压力参数、术后脑脊液sFas、sFasL水平等指标进行PCA。PCA后提取主成分作为自变量,以患者术后是否出现脑积水为因变量,应用Logistic回归分析探讨相关影响因素。结果单因素分析和PCA结果显示,脑组织损伤部位、手术前后GCS评分、脑室系统内出血、导水管和环池结构,术后颅内感染、术后大面积脑梗死、术后腰穿脑脊液置换术及术后脑脊液压力(cerebrospinal fluid pressure,CSFP)、ICP相关系数(regression of amplitude and pressure,RAP)和脑脊液sFas/sFasL水平均与患者术后继发脑积水有关(P<0.05)。PCA-Logistic回归模型显示,合并颅底损伤,手术前后GCS评分降低,脑室系统内出血,导水管和环池结构不清晰,术后合并颅内感染,大面积脑梗死,脑脊液sFas、sFasL水平升高,RAP升高和CSFP升高均是颅脑损伤患者术后继发脑水肿的独立危险因素,术后进行腰穿脑脊液置换是颅脑损伤患者术后继发脑积水的保护因素(P<0.05)。结论术后脑脊液sFas、sFasL水平和压力参数均是创伤性颅脑损伤患者术后继发脑积水的独立影响因素,对患者术后并发脑积水有一定的预测价值。
文摘Objectives To investi gate the association of soluble Fas ligand( sFasL) and soluble Fas receptor( sFas) with human chronic con gestive heart failure( CHF) . Methods The serum level of sFasL and sFas in 33 patients with CHF (13 in cardiac function class Ⅱ, 17 in class Ⅲ, 3 in class Ⅳ, NYHA) was assessed with enzyme - linked immunosorbent assay, and was compared with that of 18 age - , blood pressure - matched patients with car diac function class Ⅰ (NYHA). Results There was no difference in the level of sFasL between the two groups [CHF group: 231. 50 + / - 84. 50 (cardiac function class Ⅱ216. 50 + / - 96. 00 , class Ⅲ 226. 80 + / - 85. 70, class Ⅳ 244. 00 + / - 73. 00) vs. cardiac function class I group: 217. 50 + /-89. 00 pg/mL, P>0. 05]. However, the level of sFas was significantly higher in the patients with CHF than those of cardiac function class I group [CHF group: 1353. 30 +/-507. 71 (cardiac function class Ⅱ 1154. 85 + /-371. 20 , class Ⅲ1412.88 + /-493. 62, classⅣ1875. 67 + / - 806. 10) vs. cardiac function class I group: 983. 11+/ -461. 26 pg/mL, P<0. 05 ] . Conclusions sFasL was not associated with human CHF. However, the elevation of serum level of sFas was proportion to the severity of human CHF. sFas may play an important role in the patho- genesis of human CHF.
文摘采用酶联免疫夹心法 (EL ISA)检测了 2 5例特发性血小板减少性紫癜 (ITP)患者血清中 s Fas、s Fas L的水平。结果显示 ITP患者血清 s Fas含量为 16 .5 1± 6 .86μg/ L ,s Fas L含量为 0 .48± 0 .33μg/ L ,均显著高于正常对照 (分别为 P<0 .0 0 1和 P<0 .0 1) ;18例 ITP患者血清 s Fas水平升高 ,其中有 9例同时有 s Fas L水平升高 ,但是血清 s Fas水平升高组的血小板计数与 s Fas正常组无显著差异。提示 s Fas和 s Fas L
文摘目的:探讨血清可溶性Fas(solub le Fas,sFas)和可溶性Fas配体(solub le Fas L igand,sFasL)在再生障碍性贫血(ap lasticanem ia,AA)患者血清中的变化及临床意义。方法:采用酶联免疫吸附双抗体夹心法检测30例再生障碍性贫血患者血清sFas、sFasL水平。结果:再生障碍性贫血患者血清sFas水平显著低于正常对照(P<0.01);重型再生障碍性贫血患者血清sFas水平明显低于慢性再生障碍性贫血(P<0.05);血清sFas浓度与再生障碍性贫血患者临床分型和疗效相关。血清sFasL水平在再生障碍性贫血患者和正常对照血清中含量差异无显著性(P>0.05)。结论:AA患者血清sFas水平降低,可作为反映AA病情严重程度和疗效观察的有效指标之一。
文摘目的探讨多器官功能障碍综合征(multiple organ dysfunction syndrome,MODS)患者血清sFas和sFasL浓度在MODS诊断以及病情严重程度和预后判断中的临床意义以及与血清肿瘤坏死因子α(TNFα)水平的相关性。方法采用酶联免疫吸附法(ELISA)测定36例MODS患者血清sFas、sFasL和TNFα浓度,以急性生理学与慢性健康状况评分系统(APACHE)评分和改良MODS评分评估病情严重程度,比较MODS组与对照组〔包括非全身炎症反应综合征(SIRS)对照组和健康对照组〕以及MODS组内死亡和存活患者之间血清sFas、sFasL浓度的差异,分析患者血清sFas、sFasL和TNFα浓度与病情严重程度及血清sFas和sFasL与TNFα浓度的相关性。结果MODS患者血清sFas、sFasL浓度均明显高于非SIRS对照组和健康对照组(P<0.05或P<0.01),且与病情严重度评分均呈正相关(P均<0.01)。MODS患者中死亡组较存活组血清sFas、sFasL浓度明显升高(P均<0.05)。MODS患者血清TNFα浓度较非SIRS对照组和健康对照组明显增高,并与MODS组血清sFas、sFasL浓度呈高度正相关(P均<0.01)。MODS患者血清sFas、sFasL浓度随器官衰竭个数增加而升高。结论血清sFas、sFasL可用于临床MODS辅助诊断和协助判断病情严重程度及预后。TNFα可能促进了MODS中Fas/FasL系统表达上调。
